Tyr654
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr654  -  CTNNB1 (human)

Site Information
RNEGVAtyAAAVLFR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447585
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 3 , 5 , 14 ) , mass spectrometry ( 6 , 8 , 9 , 10 , 11 , 12 , 13 , 15 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 25 , 27 , 28 , 29 , 30 , 31 ) , mutation of modification site ( 1 , 7 , 14 , 24 , 26 , 33 ) , phospho-antibody ( 1 , 3 , 5 , 14 , 20 , 24 ) , western blotting ( 1 , 3 , 5 , 14 , 20 , 24 )
Disease tissue studied:
breast cancer ( 7 ) , colorectal cancer ( 21 , 22 , 23 , 27 , 28 , 31 ) , colorectal carcinoma ( 21 , 22 , 23 , 27 , 28 , 31 ) , gastric cancer ( 8 , 9 ) , gastric carcinoma ( 8 , 9 ) , leukemia ( 16 , 17 , 24 ) , chronic myelogenous leukemia ( 16 , 17 , 24 ) , lung cancer ( 5 , 10 , 11 , 13 , 30 ) , non-small cell lung cancer ( 5 , 10 , 11 , 30 ) , non-small cell lung adenocarcinoma ( 10 , 11 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 19 ) , non-small cell squamous cell lung carcinoma ( 30 ) , lung cancer, surrounding tissue ( 12 , 15 , 18 )
Relevant cell line - cell type - tissue:
'brain, hippocampus' ( 33 ) , 'epithelial, lung' ( 5 , 20 ) , 293T (epithelial) ( 14 ) , BC-1 (B lymphocyte) ( 24 ) , Caco-2 (intestinal) ( 25 ) , HeLa (cervical) ( 3 ) , JM1 (hepatic) ( 26 ) , K562 (erythroid) ( 16 , 17 ) , KU812 (myeloid) ( 24 ) , lung ( 10 , 11 , 12 , 13 , 15 , 18 , 19 , 20 , 29 ) , MDCKII (epithelial) ( 1 ) , MKN-45 (gastric) ( 8 , 9 ) , NCI-H358 (pulmonary) ( 5 ) , NCI-H520 (squamous) ( 30 ) , R7 ( 7 ) , SW480 (intestinal) ( 21 , 22 , 23 , 31 ) , SW620 (intestinal) ( 27 , 28 )

Upstream Regulation
Regulatory protein:
Src (human) ( 24 )
Putative in vivo kinases:
Abl (human) ( 24 ) , Src (human) ( 5 )
Kinases, in vitro:
Abl (human) ( 24 ) , EGFR (human) ( 32 ) , HER2 (human) ( 32 )
Putative upstream phosphatases:
SHP-1 (mouse) ( 14 )
Treatments:
acetaldehyde ( 25 ) , HGF ( 26 ) , imatinib ( 24 ) , SB216763 ( 24 ) , SKI-606 ( 24 )

Downstream Regulation
Effects of modification on CTNNB1:
activity, induced ( 26 ) , intracellular localization ( 1 , 7 ) , molecular association, regulation ( 14 , 20 , 24 , 26 , 33 ) , protein stabilization ( 24 )
Effects of modification on biological processes:
cell growth, altered ( 24 , 26 ) , cell growth, induced ( 7 ) , cytoskeletal reorganization ( 20 ) , transcription, altered ( 24 ) , transcription, induced ( 5 , 7 , 14 )
Induce interaction with:
HIF1A (human) ( 5 ) , SMAD2 (human) ( 5 , 20 ) , SMAD2 (mouse) ( 20 ) , Src (human) ( 5 ) , TBN (human) ( 14 ) , TCF4 (human) ( 24 )
Inhibit interaction with:
CDH1 (human) ( 26 , 33 ) , LEF-1 (human) ( 26 ) , Met (human) ( 26 ) , axin 1 (human) ( 24 )

Disease / Diagnostics Relevance
Relevant diseases:
IPF ( 20 )

References 

1

Gayrard C, et al. (2018) Src- and confinement-dependent FAK activation causes E-cadherin relaxation and β-catenin activity. J Cell Biol
29311227   Curated Info

2

Górowska-Wójtowicz E, et al. (2017) Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro 40, 324-335
28163245   Curated Info

3

Li CC, et al. (2016) Enhancement of β-catenin activity by BIG1 plus BIG2 via Arf activation and cAMP signals. Proc Natl Acad Sci U S A 113, 5946-51
27162341   Curated Info

4

Lemieux E, et al. (2015) Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer. Oncogene 34, 4914-27
25500543   Curated Info

5

Xi Y, et al. (2013) Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia. Oncogene 32, 5048-57
23246962   Curated Info

6

Rikova K (2012) CST Curation Set: 13330; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Wagh PK, et al. (2011) β-Catenin is required for Ron receptor-induced mammary tumorigenesis. Oncogene 30, 3694-704
21423209   Curated Info

8

Possemato A (2011) CST Curation Set: 11925; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Possemato A (2011) CST Curation Set: 11926; Year: 2011; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Ren H (2011) CST Curation Set: 11791; Year: 2011; Biosample/Treatment: cell line, FAC 13T/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Tucker M (2011) CST Curation Set: 10943; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Tucker M (2011) CST Curation Set: 10952; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Simoneau M, et al. (2011) SHP-1 inhibits β-catenin function by inducing its degradation and interfering with its association with TATA-binding protein. Cell Signal 23, 269-79
20840866   Curated Info

15

Tucker M (2010) CST Curation Set: 10314; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Possemato A (2010) CST Curation Set: 9956; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

17

Possemato A (2010) CST Curation Set: 9953; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

18

Hu Y (2010) CST Curation Set: 8707; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Ren H (2009) CST Curation Set: 8180; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Kim KK, et al. (2009) Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 119, 213-24
19104148   Curated Info

21

Possemato A (2007) CST Curation Set: 3613; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

22

Possemato A (2007) CST Curation Set: 3614; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

23

Possemato A (2007) CST Curation Set: 3615; Year: 2007; Biosample/Treatment: cell line, SW480/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

24

Coluccia AM, et al. (2007) Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 26, 1456-66
17318191   Curated Info

25

Sheth P, et al. (2007) Acetaldehyde dissociates the PTP1B-E-cadherin-beta-catenin complex in Caco-2 cell monolayers by a phosphorylation-dependent mechanism. Biochem J 402, 291-300
17087658   Curated Info

26

Zeng G, et al. (2006) Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 312, 3620-30
16952352   Curated Info

27

Li Y (2006) CST Curation Set: 1264; Year: 2006; Biosample/Treatment: cell line, SW620/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

28

Li Y (2006) CST Curation Set: 1265; Year: 2006; Biosample/Treatment: cell line, SW620/TSA; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Guo A (2005) CST Curation Set: 981; Year: 2005; Biosample/Treatment: tissue, lung/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Rikova K (2005) CST Curation Set: 832; Year: 2005; Biosample/Treatment: cell line, NCI-H520/serum starved; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Li Y (2005) CST Curation Set: 834; Year: 2005; Biosample/Treatment: cell line, SW480/serum starved; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

32

Miravet S, et al. (2003) Tyrosine phosphorylation of plakoglobin causes contrary effects on its association with desmosomes and adherens junction components and modulates beta-catenin-mediated transcription. Mol Cell Biol 23, 7391-402
14517306   Curated Info

33

Schuman EM, Murase S (2003) Cadherins and synaptic plasticity: activity-dependent cyclin-dependent kinase 5 regulation of synaptic beta-catenin-cadherin interactions. Philos Trans R Soc Lond B Biol Sci 358, 749-56
12740122   Curated Info